|
|
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Christophe Hézode
,
Hélène Fontaine
,
Céline Dorival
,
Fabien Zoulim
,
Dominique Larrey
et al.
Journal articles
inserm-01057763v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)
Victor De Ledinghen
,
Claire Laforest
,
Christophe Hézode
,
Stanislas Pol
,
Alain Renault
et al.
Hepatology, 2017, 64 (6), pp.1130A--1130A
Journal articles
hal-01487921v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients
Stanislas Pol
,
Marc Bourlière
,
Sandy Lucier
,
Christophe Hézode
,
Céline Dorival
et al.
Journal articles
hal-01435007v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Marc Bourlière
,
Jean-Pierre Bronowicki
,
Victor de Ledinghen
,
Christophe Hézode
,
Fabien Zoulim
et al.
Journal articles
hal-01134440v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
Christophe Hézode
,
Hélène Fontaine
,
Céline Dorival
,
Dominique Larrey
,
Fabien Zoulim
et al.
Journal articles
hal-01708037v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Christophe Hézode
,
Victor De Ledinghen
,
Hélène Fontaine
,
Fabien Zoulim
,
Pascal Lebray
et al.
Journal articles
hal-01380169v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|